Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Chromatics Color Sciences International. Inc; CCSI -- Ignore unavailable to you. Want to Upgrade?

To: STLMD who wrote (1972)	5/2/1998 6:48:00 PM
From: JanyBlueEyes	Read Replies (2) \| Respond to of 5736

As to every infant being monitored. If you think that means a bili is done, then you're wrong. If you think that a Colorimetric test will now be done on every child, you're very wrong, and let me assure you a colorimetric test at 24 hours of life in a baby going home from hospital is not going to be done. Here is an abstract from ncbi.nlm.nih.gov From Dec '96. This data was based on healthy term infants only - no preemies. It does not say what jaundice meter was used for screening nor does it point out the importance of the non-invasive aspect of the device. ========== Clinical impact of transcutaneous bilirubinometry as an adjunctive screen for hyperbilirubinemia. Dai J, Krahn J, Parry DM Department of Clinical Biochemistry, St. Boniface General Hospital, Manitoba, Canada. OBJECTIVE: To determine what the clinical impact would be of implementing a jaundice meter for use in a busy neonatal service as an adjunctive screening tool for hyperbilirubinemia. DESIGN AND METHODS: Test utilization data was collected for a 6-month period to determine how neonatal bilirubin was utilized in this hospital. The jaundice meter was evaluated in a study population of healthy term infants. The performance characteristics of the meter and the test utilization data were used to predict the clinical impact a meter could have on screening for hyperbilirubinemia. RESULTS: Utilization data indicated that about 60% of all single bilirubin neonatal testing (i.e., bilirubin only ordered) was done by normal nurseries. A jaundice meter cutoff decision reading of 17 was shown to have a sensitivity of 100% and a specificity of 68% for hyperbilirubinemia (> 260 mumol/L) in a study population of healthy term infants. From this data, it was estimated that use of a jaundice meter could eliminate 43% of the single (i.e., not combined with other tests) bilirubin tests done on healthy term neonates with no prior exposure to phototherapy. This constitutes an overall 20% reduction in bilirubin testing in normal nurseries when testing done on babies exposed to phototherapy and combined bilirubin testing are taken into consideration. Additionally, it was shown that there would be an improvement of 9% in the prediction of hyperbilirubinemia without loss of 100% sensitivity. CONCLUSION: Use of a jaundice meter in normal nurseries as an adjunctive screening tool enhances patient care by reducing the overall blood procurement rate in normal nurseries by 20% and increasing screening efficiency for significant hyperbilirubinemia by 5%.

To: STLMD who wrote (1972)	5/2/1998 8:29:00 PM
From: Manfred	Respond to of 5736

I am in TAVA too, my firend. You may have a clue to the y2k story but you have no clue as to the ccsi market size. I wonder if you really are a doctor. But since I think positive, I suppose you are telling us the truth. Please read my posts more carefully (I hope you do your job better): the WHO number is the number of the yearly newborns. You should know this number. I hope you reply after you checked your numbers. They are ridiculous. If you don't do your DD, I will have to admit that you have other motivations. If you participated at the convention, you could speak with Dr Maisels and Dr Holzman (leading pediatrics). Why do you think they risk their reputation with ccsi? Awaken, Doc. Manfred